Abstract
Recently we have observed significant increase in antidiabetic medication. There have been launched new oral antidiabetic drugs as well as new types of insulin.
Especially concentrated insulins like insulin lispro 200 U/ml and insulin glargin 300 U/ml were found very popular. Insulin lispro 200 U/ml is in principle "only" a concentrated version of its predecessor, they are bioequivalent, they have same pharmacokinetic and pharmacodynamic.
The advantage is in reduced injected volume, which mainly patients using high doses of insulin will welcome. In contrast insulin glargin 300 U/ml has different characteristics compared to insulin glargin 100 U/ml, they are not bioequivalent.
It brings a limited risk of hypoglycaemia, lower variability, extended duration of activity, flexibility in administration, lower volume and favourable effect on body weight.